Indoco Remedies Limited released its financial results for the quarter ending December 31, 2024 (Q3 FY25), reporting a decline in revenue and a net loss due to increased expenses and operational challenges.
Key Financial Highlights (Q3 FY25):
- Revenue from Operations:
₹410.55 crore, down 6.2% YoY from ₹436.66 crore in Q3 FY24.
This includes:- ₹402.45 crore from core operations.
- ₹8.10 crore from other operating income.
- Total Income:
₹411.40 crore, a 5.3% decline compared to ₹434.22 crore in Q3 FY24. - Total Expenses:
₹443.35 crore, up slightly from ₹439.06 crore in Q3 FY24. Key contributors include:- ₹107.55 crore for employee benefits expenses.
- ₹166.39 crore for R&D and other operational costs.
- Profit/Loss:
- Net Loss: ₹28.40 crore, compared to a net loss of ₹10.01 crore in Q3 FY24.
- Profit Before Tax (PBT): ₹(30.96) crore, versus ₹(4.84) crore in Q3 FY24.
- EBITDA MARGIN 2.93% VS 13.69% (YOY)
Nine-Month Performance (FY25):
- Revenue from Operations:
₹1,252.40 crore, a decline from ₹1,349.14 crore in the corresponding period of FY24. - Net Loss:
₹36.61 crore, compared to a loss of ₹26.61 crore in the same period last year.
Commentary:
The decline in revenue and rising operational costs continue to pose challenges for Indoco Remedies. The company remains focused on optimizing operations and managing costs to navigate current market dynamics effectively.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Always conduct your research or consult a financial advisor before making investment decisions.
TOPICS:
Indoco Remedies